Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05156281 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

A Phase 3 study of Relapsing Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
1,011
Enrollment target
20
Study locations

NCT05156281 is a Phase 3 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 1,011 participants, below the 2,125-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05156281, a Phase 3 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,011 participants
Enrollment target
20
Study locations

Study Summary

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Conditions Studied

Relapsing Multiple Sclerosis

Interventions

  • DRUG Teriflunomide
  • DRUG Remibrutinib

Study Locations (20)

Florida

  • Nova Clinical Research LLC - Bradenton
  • University of Florida - Gainesville
  • Memorial Healthcare System - Hollywood
  • Mayo Clinic Jacksonville - Jacksonville
  • Neurology Associates PA - Maitland
  • Gables Neurology - Miami
  • UM Department Of Neurology - Miami
  • Aqualane Clinical Research - Naples
  • Advent Health Orlando - Orlando
  • Humanity Clinical Research - Pembroke Pines
  • Emerald Coast Neurology - Pensacola

California

  • Vladimir Royter MD APMC - Hanford
  • VA Greater LA Healthcare System - Los Angeles
  • Regina Berkovich MD PhD Inc - West Hollywood

Colorado

  • CU Anschutz Med Campus - Aurora
  • Colorado Neurological Research PC - Denver

District of Columbia

  • Georgetown University Hospital Research - Washington D.C.
  • Georgetown University Hospital - Washington D.C.

Arizona

  • Ctr for Neurology and Spine - Phoenix

Connecticut

  • New England Institute for Clinical Research - Stamford

Trial Details

FieldValue
Enrollment Target 1,011 participants
Start Date 2021-12-13
Est. Completion 2030-10-30
Phase Phase 3

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05156281

The ClinicalTrials.gov registry entry for NCT05156281 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,011 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,125-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (52% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Teriflunomide is the first listed.

NCT05156281 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT05156281 about?

NCT05156281 is a clinical study titled "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)". To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

What is the current status of trial NCT05156281?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,011 participants. The study started on 2021-12-13. Estimated completion is 2030-10-30.

What conditions does trial NCT05156281 study?

This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.

What interventions are being tested in trial NCT05156281?

The interventions under investigation include: Teriflunomide (DRUG), Remibrutinib (DRUG).

Who is sponsoring clinical trial NCT05156281?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05156281 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Multiple Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.